Back to results
US 12,653,901 B2Granted
Anti-EDB antibodies and antibody-drug conjugates
AssigneePfizer Inc.
InventorsAndrea Therese Hooper, Kimberly Ann Marquette, Chakrapani Subramanyam, Hans-Peter Gerber, Chad Michael May
Life of this patent
Estimating the term…
Abstract
The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.
Claims4
A process for producing an antibody-drug conjugate:
- wherein the antibody-drug conjugate comprises:
- (a) an antibody, or antigen binding fragment thereof, that binds to extra domain B of fibronectin, wherein the antibody, or antigen binding fragment thereof, comprises a heavy chain variable region comprising SEQ ID NO:21 and a light chain variable region comprising SEQ ID NO:10;
- (b) a linker;
- and
- (c) a drug;
- and
- wherein the process comprises:
- (i) conjugating the linker to the antibody, or antigen binding fragment thereof, to form the conjugate of the linker and the antibody, or antigen binding fragment thereof;
- and
- conjugating the drug to the conjugate of the linker and the antibody, or antigen binding fragment thereof;
- or
- (ii) conjugating the linker and the drug, to form a linker-drug conjugate;
- and
- conjugating the antibody, or antigen binding fragment thereof, to the linker-drug conjugate.
11 more elements
A process for producing an antibody-drug conjugate:
- wherein the antibody-drug conjugate comprises:
- (a) an antibody, or antigen binding fragment thereof, that binds to extra domain B of fibronectin and that comprises a heavy chain comprising SEQ ID NO:25 and a light chain comprising SEQ ID NO:
- 31;
- (b) a cleavable linker;
- and
- (c) a cytotoxic agent;
- wherein the process comprises:
- (i) conjugating the linker to the antibody, or antigen binding fragment thereof, to form the conjugate of the linker and the antibody, or antigen binding fragment thereof;
- and
- conjugating the drug to the conjugate of the linker and the antibody, or antigen binding fragment thereof;
- or
- (ii) conjugating the linker and the drug, to form a linker-drug conjugate;
- and
- conjugating the antibody, or antigen binding fragment thereof, to the linker-drug conjugate;
- wherein the cleavable linker, the cytotoxic agent, and the antibody, or antigen binding fragment thereof, are linked to generate the structure:
- wherein:
- X-S represents the antibody, or antigen binding fragment thereof, and S is the sulfur atom of at least one cysteine residue in the antibody, or antigen binding fragment thereof.
14 more elements
Dependencies are inferred from the claim text.